You are here

Handling of COVID-19 in Bioiberica

17 Mar 2020

Important corporate statement.

The pandemic spread of the Coronavirus has increased concern about the potential disruption to the manufacture and distribution of goods.

As a life science company, it is our responsibility to keep working to ensure the production and distribution of all our active pharmaceutical ingredients and products, with the highest quality and safety standards, while safeguarding the health of our employees. 

Therefore, we are closely monitoring the situation by keeping in contact with the authorities and with our suppliers in order to protect every aspect of our manufacturing and supply operations and to take steps to prevent impact. We are operating under the restrictions inherent in these circumstances, with part of our staff working from home, while ensuring our activity at productions sites.

Thanks to the commitment of our team, we strive to ensure, as far as possible, supply as usual for our customers and partners.

Related News

16 Oct 2023

We participated in CPHI 2023 in Barcelona, ​​where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.

4 May 2023

They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs

28 Apr 2023

Join Bioiberica at stand F130 in Geneva, 9-11 May to discover the company’s latest science and insights driving innovation in the nutraceuticals market.